Open AccessInfliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
Author(s) -
Brigida Barberio,
Fabiana Zingone,
R. D’Incà,
Laura Rovigo,
Lorenzo Bertani,
Giorgia Bodini,
Matteo Ghisa,
A. Gubbiotti,
Davide Massimi,
Greta Lorenzon,
Edoardo Savarino
Publication year - 2020
Publication title -
clinical and translational gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.673
H-Index - 35
ISSN - 2155-384X
DOI - 10.14309/ctg.0000000000000177
Subject(s) - medicine , infliximab , adalimumab , ulcerative colitis , biosimilar , tolerability , adverse effect , inflammatory bowel disease , crohn's disease , gastroenterology , colonoscopy , surgery , disease , colorectal cancer , cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom